Latest news with #CorePlus
Yahoo
2 days ago
- Health
- Yahoo
AIxMed and CorePlus Partner to Demonstrate a Digital Urine Cytology Workflow Solution
AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics. SANTA CLARA, Calif., May 30, 2025 /PRNewswire/ -- AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus have entered a Memorandum of Understanding to evaluate a Quality Control workflow solution for urine cytology. The partnership aims to demonstrate the integration of artificial intelligence into the urine cytology workflow, enhancing diagnostic consistency, efficiency, and scalability. AIxMed's experience in AI-based cytology software and analysis, combined with CorePlus' experience in integrating digital and AI solutions into their day-to-day pathology workflow will come together to provide an end-to-end solution for research-use only cytology analysis. "We are thrilled to collaborate with CorePlus in demonstrating how AIxURO can seamlessly integrate into their digital pathology workflow. This effort builds on the success of our previous studies and marks an important milestone toward modernizing cytology quality control (QC) through digital and AI tools," said Samuel Chen, CEO of AIxMed. "AIxURO offers significant time savings with consistent results. Integrating our scanner with real-time AI-based QC checks significantly improves efficiency and diagnostic accuracy. Precision cytology is no longer a vision—it's reality," said Mariano de Socarraz, Founder, and CEO of CorePlus. The scarcity of cytologists and the manual process involved in cell characterization necessitate the development of advanced tools to enhance workflow and offer both quantitative and qualitative insights. AI-driven computational tools have the potential to provide these valuable insights and enable the processing of a greater number of slides with the existing workforce. To learn more about these solutions or to request a demonstration, please visit About AIxMedFounded in 2018, AIxMed is creating a roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform. This solution simplifies clinical workflows and richly strengthens the quality of healthcare by aiding critical decision support during clinical diagnosis and monitoring. To learn more visit About CorePlusCorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. To learn more visit View original content to download multimedia: SOURCE AIxMed, Inc.
Malaysian Reserve
5 days ago
- Health
- Malaysian Reserve
CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ — CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance. Revolutionizing Cytology with AI and Digital Pathology As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples. The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy. Outstanding Results and Operational Efficiency The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included: 97% accuracy 82% sensitivity 99% specificity 98% negative predictive value 86% positive predictive value In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency. A New Standard for Quality Control in Cervical Cytology Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care. 'We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!' Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. 'Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact.' For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System – Rivera Rolon – 2025 – Cancer Cytopathology – Wiley Online Library About CorePlus CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. About Cancer Cytopathology Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information.
Yahoo
5 days ago
- Health
- Yahoo
CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ -- CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance. Revolutionizing Cytology with AI and Digital Pathology As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples. The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy. Outstanding Results and Operational Efficiency The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included: 97% accuracy 82% sensitivity 99% specificity 98% negative predictive value 86% positive predictive value In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency. A New Standard for Quality Control in Cervical Cytology Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care. "We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!" Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. "Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact." For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System - Rivera Rolon - 2025 - Cancer Cytopathology - Wiley Online Library About CorePlus CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. About Cancer Cytopathology Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information. View original content to download multimedia: SOURCE CorePlus Servicios Clinicos y Patologicos, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-04-2025
- Business
- Yahoo
Blackstone Inc (BX) Q1 2025 Earnings Call Highlights: Record Inflows and AUM Amid Market Challenges
GAAP Net Income: $1.2 billion for the first quarter. Distributable Earnings: $1.4 billion, or $1.09 per common share. Dividend Declared: $0.93 per common share. Fee-Related Earnings Growth: 9% year-over-year. Assets Under Management (AUM): Increased 10% year-over-year to nearly $1.2 trillion. Inflows: $62 billion in Q1, highest level in three years. Management Fees: Increased 11% to a record $1.9 billion in Q1. Net Realizations Increase: 22% year-over-year. Performance Revenue Eligible AUM: Reached a record $583 billion, up 13% year-over-year. Infrastructure Appreciation: 7.5% in the quarter and 24% for the last 12 months. Corporate Private Equity Funds Appreciation: 1.1% in the quarter and 14% for the last 12 months. Non-Investment Grade Private Credit Strategies Return: 2.7% in the quarter and 15% for the last 12 months. Core Plus Real Estate Funds Appreciation: 1.2% in the first quarter. Warning! GuruFocus has detected 6 Warning Signs with BX. Release Date: April 17, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Blackstone Inc (NYSE:BX) reported strong first-quarter results with distributable earnings up 11% year-over-year to $1.4 billion. The company raised $62 billion in inflows in Q1, the highest level in three years, contributing to a record $1.2 trillion in assets under management. Blackstone's private credit business has expanded significantly, with $465 billion in assets, driven by strong performance and structural tailwinds. The firm's private wealth platform continues to grow, with $270 billion in assets, and new strategic alliances with Wellington and Vanguard aim to democratize private markets. Blackstone's infrastructure platform saw a 36% year-over-year increase in assets under management, with strong performance in data centers and other areas. Uncertainty around tariffs and their potential impact on economic growth and inflation poses risks to investor sentiment and market conditions. Realization activity is expected to be affected by policy-driven uncertainty and market volatility, potentially impacting near-term earnings. The direct first-order exposure to tariffs is limited, but there are potential material impacts on a small group of portfolio companies. The IPO market is currently challenging, with conditions being the toughest among capital markets, affecting potential exits. The North American institutional channel faces fundraising headwinds due to continued realization challenges and a mature market environment. Q: Can you discuss the deployment opportunity with nearly $180 billion of dry powder, given the current uncertain and volatile environment? A: Jonathan Gray, President and COO, explained that during periods of dislocation, Blackstone accelerates deployment in areas where security values have decoupled due to technical factors. They are looking at public companies and sectors with long-term conviction, such as digital infrastructure and energy. The firm is well-positioned to take advantage of opportunities with $177 billion of dry powder. Q: Why do private market solutions work well in all environments, and how does Blackstone emerge stronger from periods of volatility? A: Jonathan Gray highlighted that Blackstone's model is designed for stress periods, with almost no net debt and $177 billion of dry powder. This allows them to be counter-cyclical, leaning in when prices drop. The long-term nature of their investments and the ability to hold assets without being forced sellers contribute to their resilience and strength. Q: What is your outlook for fundraising in the North American institutional channel, given continued realization headwinds? A: Jonathan Gray noted that while decision-making may slow due to the environment, North American clients remain committed to private assets. Certain segments like secondaries, infrastructure, and credit are in favor. The overall bias is towards more alternatives, driven by strong returns. Q: Can you comment on the opportunity to expand the global wealth management business, particularly with the Wellington and Vanguard partnership? A: Jonathan Gray emphasized the significant growth potential in the wealth area, with Blackstone's strong brand and history in private wealth. The partnership with Wellington and Vanguard aims to create holistic solutions for individual investors, enhancing access to private market solutions. Q: How do you assess the direct impact of tariffs on your portfolio, and how is your direct lending business holding up? A: Jonathan Gray stated that the direct impact of tariffs is limited to a small group of companies affected by supply chain costs. The broader impact depends on market volatility and economic slowdown. The direct lending business is resilient, with lower leverage compared to past cycles, and is expected to withstand potential stresses. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
